Updated: LHA Life Sciences & Medical Technologies Virtual Conference
Thursday, June 28, 2012 The event will feature 30-minute corporate presentations with accompanying slides by executives from seven industry leaders.
Presentations begin at 9:00 a.m. Eastern Time and can be accessed at www.informedinvestors.com. Individual presentations also will be available at each presenting company's website.
We hope you can join us.
If you cannot attend the live event, presentations will be archived at www.informedinvestors.com and at each presenting company's website for approximately 90 days. If you have any questions, please call Carolyn Curran at (212) 838-3777 or firstname.lastname@example.org.
Time (Eastern Time) Company Ticker Symbol Website 9:00 a.m. CAS Medical Systems, Inc. Nasdaq: CASM www.casmed.com 9:30 a.m. Chembio Diagnostics, Inc. NasdaqCM: CEMI www.chembio.com 10:00 a.m. Derma Sciences, Inc. NasdaqCM: DSCI www.dermasciences.com 10:30 a.m. PhotoMedex, Inc. NasdaqGM: PHMD www.photomedex.com 11:30 a.m. Spherix, Inc. NasdaqCM: SPEX www.spherix.com 12:00 p.m. Tonix Pharmaceuticals. OTCBB: TNXP www.tonixpharma.com 12:30 p.m. NovelosTherapeutics OTCBB: NVLT www.novelos.com LHA is a leading independent investor relations firm. As IR specialists with more than 25 years of experience, we partner with public and soon-to-be public companies to create and support best practices investor and media relations programs. By focusing on the development of public company identity and the communication of strategic vision, we build awareness, enthusiasm and sponsorship among target audiences in the investment community to maximize valuation.
Our programs deliver measurable results so clients can assess the impact of their investor relations initiatives.
LHA Life Sciences & Medical Technologies Virtual Conference June 28, 2012 beginning at 9:00 a.m. Eastern Time 9:00 a.m. Eastern Time CAS Medical Systems is a leading developer and manufacturer of medical devices for non-invasive patient monitoring.
The Company's FORE-SIGHT@ Absolute Cerebral Oximeter is the only cerebral oximeter available with FDA clearance for non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation for all patients, regardless of age or weight. Direct monitoring of tissue oxygenation provides a unique and powerful tool to alert clinicians to otherwise unrecognized and dangerously low levels of oxygenation of the brain and other tissues, thereby allowing them to intervene appropriately in the care of their patients. In addition to FORE-SIGHT Oximeters and accessories, the Company provides a line of bedside patient vital signs monitoring products, proprietary non-invasive blood pressure monitoring solutions for OEM use, neonatal intensive care supplies, and service. CASMED products are designed to meet the needs of a full spectrum of patient populations worldwide, ranging from adults to pediatrics and neonates. For additional information please visit www.casmed.com.
9:30 a.m. Eastern Time Chembio Diagnostics develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $10 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by Alere, Inc. (formerly, Inverness Medical Innovations, Inc.). Chembio markets its HIV STAT-PAK@ line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio has developed a patented point-of-care test platform technology, the Dual Path Platform (DPP@) technology, which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP@. Headquartered in Medford, NY, with approximately 170 employees, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U. S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13.485. For additional information please visit www.chembio.com.
10:00 a.m. Eastern Time Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products, advanced wound care dressings and traditional dressings. Derma Sciences has successfully completed the Phase 2 clinical trial in diabetic foot ulcer healing with DSC127, an investigational pharmaceutical drug under development for accelerated wound healing and scar reduction, and is preparing to begin Phase 3 clinical trials. Its MEDIHONEY@ product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB@ for better management of wound exudate, BIOGUARD@ for infection prevention and TCC-EZT, a gold-standard treatment for diabetic foot ulcers. For additional information please visit www.dermasciences.com.
12:30 p.m. Eastern Time Novelos is a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer. The Company's three cancer-targeted compounds are selectively taken up and retained in cancer cells, including cancer stem cells, versus normal cells.
Thus, Novelos' therapeutic compounds appear to directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy versus all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. I-124-CLR1404 (LIGHT) is a small-molecule cancer-targeted PET imaging agent which the Company believes has first-in-class potential and for which Phase 1-2 clinical trials are ongoing. I-131-CLR1404 (HOT) is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. The Company believes HOT also has first-in-class potential. HOT Phase 1b dose-escalation trial is ongoing and is expected to enter Phase 2 trials in the first quarter of 2013 as a monotherapy for solid tumors with significant unmet medical need, subject to additional funding. CLR1404 (COLD), a pre-clinical cancer-targeted non-radioactive chemotherapy, works primarily through Akt inhibition. Together, Novelos believes its compounds are able to "find, treat and follow" cancer anywhere in the body in a novel, effective and highly selective way. For additional information please visit www.novelos.com.
10:30 a.m. Eastern Time PhotoMedex is a global skin health company providing integrated disease management and aesthetic solutions to dermatologists, professional aestheticians and consumers. The company provides proprietary products and services that address skin diseases and conditions including psoriasis, vitiligo, acne, actinic keratosis (a precursor to certain types of skin cancer) and photo damage. Its experience in the physician market provides the platform to expand its skin health solutions to spa markets, as well as traditional retail, online and infomercial outlets for home-use products. As a result of its December 2011 merger with Radiancy Inc., PhotoMedex has added a range of home-use devices under the no!no!T brand, for various indications including hair removal, acne treatment and skin rejuvenation. The company also offers a professional product line for acne clearance, skin tightening, psoriasis care and hair removal sold to physician clinics and spas. For additional information please visit www.photomedex.com.
11:30 a.m. Eastern Time Spherix was launched in 1967 as a scientific research company under the name Biospherics Research. The Company now leverages its scientific and technical expertise and experience through its two subsidiaries - Biospherics Incorporated and Spherix Consulting, Inc. Biospherics is dedicated to developing and licensing/marketing proprietary therapeutic products for treatment of diabetes, metabolic syndrome and atherosclerosis. Biospherics is actively seeking a pharmaceutical partner to continue the development of its Phase 3 compound for the treatment of diabetes, D-tagatose, while exploring new drugs and combinations for treatment of high triglycerides, a risk factor for atherosclerosis, myocardial infarction, and stroke. Spherix's Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products and industrial chemicals and pesticides. For additional information please visit www.spherix.com.
12:00 p.m. Eastern Time Tonix is developing innovative prescription medications for challenging disorders of the central nervous system.
The Company targets conditions characterized by significant unmet medical need, inadequate existing treatment options, and high dissatisfaction among both patients and physicians. TONIX's core technology improves the quality of sleep in patients with chronic pain syndromes. TONIX's lead products are designed to be fundamental advances in sleep hygiene and pain management and to be safer and more effective than currently available treatments. TONIX's products are the result of a program to harvest advances in science and medicine to search for potential therapeutic solutions among known pharmaceutical agents. TONIX is developing new formulations that have been optimized for new therapeutic uses. Its most advanced product candidates, TNX-102 for FM and TNX-105 for PTSD, are novel dosage formulations of cyclobenzaprine, the active ingredient in two U.S. FDA-approved muscle relaxants. For additional information please visit www.tonixpharma.com.
SOURCE LHA -0- 06/27/2012 /Web Site: http://www.informedinvestors.com CO: LHA ST: New York IN: HEA MTC BIO PHA HOU SU: CCA PRN -- CL31906 -- 0000 06/27/2012 17:33:00 EDT http://www.prnewswire.c